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Huntington’s disease (HD) is a genetic disorder caused by an expanded CAG repeat in the huntingtin 
gene, and although there are currently no disease-modifying treatments, there is much excitement about 
the prospect of treatments targeting huntingtin expression. In a phase I/2A trial of an antisense 
oligonucleotide (ASO) treatment (Tominersen), no serious adverse events were recorded, and there was 
a dose-dependent reduction in cerebrospinal fluid (CSF) huntingtin levels1. In an open-label extension 
(OLE) study, patients received monthly or bimonthly Tominersen, with preliminary data confirming 
the reduction in mutant huntingtin levels2. Here we report on a unique major adverse effect occurring 
during this OLE.  
 
A 54 year old man with a pathogenic huntingtin CAG repeat of 42, received monthly intrathecal 
Tominersen during the OLE, having received four doses of intrathecal placebo during the prior phase 
I/2A trial. At the start of the OLE he had modest chorea and broken ocular pursuit, with a total Unified 
Huntington’s Disease Rating Scale (UHDRS) motor score of 12. His mobility was normal, and he 
performed tandem gait without support, and he was still working. 
 
Following his fifth monthly dose of Tominersen, he developed gait difficulties, with an unsteady broad-
based gait along with mild finger-nose and heel-shin ataxia, and an inability to perform a tandem gait. 
He initially continued to receive monthly Tominersen, but his gait deteriorated over the following three 
months and he started to fall, and could no longer work. His UHDRS motor score increased to 38. 
 
His clinical deterioration was accompanied by a progressive rise in CSF protein, peaking at 2.64 g/l, 
and a CSF lymphocytosis, peaking at 46 cells/mm3 (Figure 1A and 1B). Serial brain MRI revealed 
increasing ventricular dilation, with periventricular oedema, consistent with hydrocephalus (Figure 1C 
and 1D). His gait improved dramatically following a high-volume CSF tap, and lumbar infusion studies 
confirmed increased resistance to CSF outflow (Figure 1E). A ventriculo-peritoneal shunt was therefore 





This ASO therapy has led to much excitement within the HD community, but the published clinical 
data are limited, with no major serious adverse events reported. Here we report for the first time on a 
patient in receipt of this therapy who developed a communicating hydrocephalus that we diagnosed as 
being secondary to a sterile meningitis induced by Tominersen. This resulted in significant disability, 
which benefited from shunting. 
 
Clinical experience with intrathecal ASO therapy is limited, but does include the use of the intrathecal 
ASO treatment (Nusinersen) for spinal muscular atrophy3,4. Although no cases of hydrocephalus were 
seen in trials of this drug, during post-marketing surveillance a number of cases of aseptic meningitis 
and communicating hydrocephalus were observed5. However, this has not been reported with 
Tominersen to date and given that a large Phase 3 study is underway (NCT03761849), along with other 
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Figure 1 – Investigation results 
CSF protein (A) and leukocyte count (B). Light and dark grey bars represent treatment with placebo 
and Tominersen respectively. Arrow indicates clinical deterioration. Axial T2-weighted MRI at 
baseline (C) and after deterioration (D). Lumbar infusion study (E). AMP=pulse amplitude; HR=heart 
rate; ICP=intracranial pressure; RAP=compensatory reserve index. 
 
